USPSTF Finds Evidence Lacking for Autism Screening in Children

Share this content:
USPSTF Finds Evidence Lacking for Autism Screening in Children
USPSTF Finds Evidence Lacking for Autism Screening in Children

TUESDAY, Aug. 4, 2015 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) has concluded that there is currently insufficient evidence to assess the benefits and harms of screening for autism spectrum disorder (ASD) in asymptomatic children age 3 and younger. These findings form the basis of a draft recommendation statement published online Aug. 3 by the USPSTF.

Researchers from the USPSTF reviewed the evidence relating to the benefits and harms of routine ASD screening in primary care settings. Data were reviewed from 17 studies of screening instruments for use in young (3 years old or younger), unselected populations.

The researchers found insufficient direct evidence on the benefits of screening for ASD in toddlers and preschoolers. Insufficient evidence was found on the efficacy of treatment of cases of screening-detected ASD. Overall, the current evidence was insufficient to assess the balance of benefits and harms of screening in a population of children who have not been diagnosed with ASD or developmental delay and for whom no concerns have been raised by their parents or clinical providers. The findings form the basis of a recommendation statement, which will available for comment from Aug. 4 to Aug. 31.

"More clear evidence is needed before the Task Force can recommend for or against screening all children who don't have any signs of the condition," David Grossman, M.D., M.P.H., vice chair of the USPSTF, said in a statement.

Evidence Review
Draft Recommendation Statement
Comment on Recommendation

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths